← Back to all trials
Completed
NCT04837222
A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
Conditions: Lymphoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 1000
Sponsor: Takeda
Location: Anhui Provincial Cancer Hospital Hefei Anhui
Summary
Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to their clinic's standard practice.
The main aim of this study is to collect information on any side effects from treatment with brentuximab vedotin. Other aims are to collect information on how brentuximab vedotin is used to treat these participants and the outcomes of these participants.
Eligibility Criteria
Inclusion Criteria:
1. Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin.
2. CD30-positive lymphoma by INV (any CD30 expression)
Exclusion Criteria:
1\. Who currently participates in or with plan to participate in any interventional clinical trial.
Source: ClinicalTrials.gov (NCT04837222). StuddyBuddy aggregates publicly available trial information.
